ORLANDO, Fla.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) today announced the results of a biomarker analysis which indicated that in metastatic colorectal cancer (mCRC) patients who have failed all other chemotherapeutic regimens, the efficacy of Vectibix™ (panitumumab) monotherapy is confined to patients with non-mutated (wild-type) KRAS tumors. Specifically, in patients with non-mutated KRAS tumors, Vectibix significantly increased progression-free survival (PFS) and had an impact on quality of life (QoL) and disease-related symptoms, compared to best supportive care (BSC) alone. These data will be presented at an oral presentation on Saturday, January 26th at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
